Welling­ton lines up a $393M bankroll for its next round of pri­vate biotech bets — and they’re like­ly think­ing big

Welling­ton Man­age­ment made some un­cus­tom­ary waves at the be­gin­ning of the year when it threw its con­sid­er­able weight against Bris­tol-My­ers Squibb’s $74 bil­lion Cel­gene buy­out. But af­ter Bris­tol-My­ers’ biggest in­vestor con­ced­ed that game to the in­flu­en­tial proxy firms in­volved, they’re now go­ing to end the year by rolling out a big new in­vest­ment fund for a new sta­ble of fledg­ling biotechs on the pri­vate side of the in­dus­try.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.